RATIONALE: Methamphetamine (MA) increases extracellular dopamine (DA) and at chronic high doses induces toxicity as indicated by decreased expression of tyrosine hydroxylase (TH) and dopamine transporter (DAT). Notably, rats will self-administer MA in escalating quantities producing such toxicity. However, the impact of MA at sub-toxic doses on DA regulation is not well established. OBJECTIVE: The temporal dynamics of DA regulation following cessation of sub-toxic escalating and binge doses of non-contingent MA were investigated as changes therein may be associated with escalation of MA intake. MATERIALS AND METHODS: MA was administered 3×/day using an established 14-day escalating-dose regimen (0.1-4.0 mg/kg) or a single-day binge-style administration (3 × 4 mg/kg). DA tissue content, DA turnover, TH protein, TH phosphorylation, DAT, and vesicular monoamine transporter 2 were measured in nigrostriatal and mesoaccumbens pathways 48 h and 2 weeks after MA cessation. RESULTS: Changes in striatal DA regulation were limited to increased DA turnover. However, in the mesoaccumbens pathway, escalating MA had biphasic effects. DA was increased in ventral tegmental area (VTA) and decreased in nucleus accumbens at 48 h post-MA while the reverse was seen at 2 weeks. These changes were matched by similar changes in TH protein and, in the VTA, by changes in DAT. CONCLUSION: Escalation of MA intake produces both transient and long-lasting effects upon DA, TH, and DAT in the mesoaccumbens pathway. The eventual decrease of DA in the VTA is speculated to contribute to craving for MA and, thus, may be associated with MA escalation and resulting dopaminergic toxicity.
RATIONALE: Methamphetamine (MA) increases extracellular dopamine (DA) and at chronic high doses induces toxicity as indicated by decreased expression of tyrosine hydroxylase (TH) and dopamine transporter (DAT). Notably, rats will self-administer MA in escalating quantities producing such toxicity. However, the impact of MA at sub-toxic doses on DA regulation is not well established. OBJECTIVE: The temporal dynamics of DA regulation following cessation of sub-toxic escalating and binge doses of non-contingent MA were investigated as changes therein may be associated with escalation of MA intake. MATERIALS AND METHODS: MA was administered 3×/day using an established 14-day escalating-dose regimen (0.1-4.0 mg/kg) or a single-day binge-style administration (3 × 4 mg/kg). DA tissue content, DA turnover, TH protein, TH phosphorylation, DAT, and vesicular monoamine transporter 2 were measured in nigrostriatal and mesoaccumbens pathways 48 h and 2 weeks after MA cessation. RESULTS: Changes in striatal DA regulation were limited to increased DA turnover. However, in the mesoaccumbens pathway, escalating MA had biphasic effects. DA was increased in ventral tegmental area (VTA) and decreased in nucleus accumbens at 48 h post-MA while the reverse was seen at 2 weeks. These changes were matched by similar changes in TH protein and, in the VTA, by changes in DAT. CONCLUSION: Escalation of MA intake produces both transient and long-lasting effects upon DA, TH, and DAT in the mesoaccumbens pathway. The eventual decrease of DA in the VTA is speculated to contribute to craving for MA and, thus, may be associated with MA escalation and resulting dopaminergic toxicity.
Authors: Jun Wang; Sebastien Carnicella; Somayeh Ahmadiantehrani; Dao-Yao He; Segev Barak; Viktor Kharazia; Sami Ben Hamida; Agustin Zapata; Toni S Shippenberg; Dorit Ron Journal: J Neurosci Date: 2010-10-27 Impact factor: 6.167
Authors: Michael F Salvatore; Jin-Lu Zhang; Delia M Large; Patsy E Wilson; Clelland R Gash; Theresa Currier Thomas; John W Haycock; Guoying Bing; John A Stanford; Don M Gash; Greg A Gerhardt Journal: J Neurochem Date: 2004-07 Impact factor: 5.372
Authors: Ronald Kuczenski; David S Segal; William P Melega; Goran Lacan; Stanley J McCunney Journal: Neuropsychopharmacology Date: 2009-07-01 Impact factor: 7.853
Authors: Kymry T Jones; Catherine Woods; Juan Zhen; Tamara Antonio; Kenneth D Carr; Maarten E A Reith Journal: J Neurochem Date: 2017-01-31 Impact factor: 5.372
Authors: Rui Zhu; Tianjiao Yang; Firas Kobeissy; Tarek H Mouhieddine; Mohamad Raad; Amaly Nokkari; Mark S Gold; Kevin K Wang; Yehia Mechref Journal: PLoS One Date: 2016-04-15 Impact factor: 3.240